November 12, 2019 The future of CLL therapy we believe will include fixed duration treatments of non-chemo drugs. In this interview from EHA... November 12, 2019NewslettersBy Brad Hedrick
November 5, 2019 Dr. Danilov of OHSU talks about a new combination, Entospletinib + Obinutuzumab, that was promising activity and tolerability in a... November 5, 2019NewslettersBy Brad Hedrick
October 29, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Farrukh Awan has done research on the cardiac side effects... October 29, 2019NewslettersBy Brad Hedrick
October 22, 2019 Dear Friends and Supporters of the CLL Society, New this week! We have been asked to provide some advice on vaccines so... October 22, 2019NewslettersBy Brad Hedrick
October 8, 2019 Dear Friends and Supporters of the CLL Society, New this week! Designing the right trials for all patients takes careful planning, deep... October 8, 2019NewslettersBy Brad Hedrick
October 1, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Wiestner of the NIH discusses the importance of acalabrutinib’s ability... October 1, 2019NewslettersBy Brad Hedrick
September 24, 2019 Dear Friends and Supporters of the CLL Society, New this week! Dr. Furman discusses how he decides on what single drug or combination of... September 24, 2019NewslettersBy Brad Hedrick
September 17, 2019 Dear Friends and Supporters of the CLL Society, New this week! The trial that compared FCR to ibrutinib and rituximab for treatment... September 17, 2019NewslettersBy Brad Hedrick
September 10, 2019 Dear Friends and Supporters of the CLL Society, New this week! We need to know the total cost of therapies, but it... September 10, 2019NewslettersBy Brad Hedrick
September 3, 2019 Dear Friends and Supporters of the CLL Society, We invite you to attend our CLL Society Webinar Tuesday, Sep 10, 2019,... September 3, 2019NewslettersBy Brad Hedrick
